araag2/HINT huggingface dataset:
Clinical trial NCT01193478 (phase 1, status: completed)
Conditions: hcv infection
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: gs-5885, placebo, gs-5885, placebo, gs-5885, placebo, gs-5885, placebo, gs-5885, placebo, gs-5885, placebo
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@](N=C(O)OC)(C(C)C)C(=O)N1CC2(CC2)C[C@@]1([H])C1=NC=C(N1)C1=CC2=C(C=C1)C1=C(C=C(C=C1)C1=CC3=C(C=C1)N=C(N3)[C@@]1([H])N(C(=O)[C@@]([H])(N=C(O)OC)C(C)C)[C@]3([H])CC[C@@]1([H])C3)C2(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronically infected with HCV genotype 1

          -  HCV treatment-naïve

          -  Not co-infected with HIV or HBV

          -  HCV RNA viral load of at least 100,000 IU/mL

          -  BMI 19 to 35 kg/m2

          -  Subject agrees to use highly effective contraception methods if female of childbearing
             potential or sexually active male.

        Exclusion Criteria:

          -  History of clinically-significant illness or any other major medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol

          -  Decompensated liver disease or cirrhosis or evidence of hepatocellular carcinoma

          -  Serological evidence of co-infection with human immunodeficiency virus (HIV),
             hepatitis B virus (HBV), or another HCV genotype

          -  Subjects with known, current use of amphetamines and/or cocaine; subjects taking
             methadone or buprenorphine (opioid replacement therapy) or ongoing alcohol abuse
Clinical trial NCT01634789 (phase 1, status: terminated)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: bazedoxifene, bazedoxifene, bazedoxifene, bazedoxifene/conjugated estrogens
SMILES: CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1, CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1, CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1, CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1
Reason stopped: 
    this study was terminated on 10 december 2012 due to low enrollment. the decision to terminate
    the study was not based on safety or efficacy issues.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Generally healthy postmenopausal women

          -  Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight >= 50 kg

        Exclusion Criteria:

          -  Pregnant or nursing females; females of childbearing potential
Clinical trial NCT01870245 (phase 1, status: terminated)
Conditions: healthy volunteer
ICD codes: Y99.2
Drugs: achn-975, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Body weight between 40 and 100 kilograms (between ~88 pounds and ~220 pounds)

          -  Use of contraception

          -  Stable health

          -  Negative tests for alcohol, tobacco, and drugs of abuse

        Key Exclusion Criteria:

          -  History of clinically significant disease

          -  Pregnancy
Clinical trial NCT00003382 (phase 1, status: terminated)
Conditions: fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: gemcitabine hydrochloride, topotecan hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically documented refractory or recurrent ovarian epithelial or fallopian tube
             cancer

          -  No borderline ovarian cancer

          -  Extra-ovarian papillary serous tumors eligible

          -  Must not be eligible for any higher priority phase II or III GOG protocol

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  GOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  SGOT no greater than 3 times upper limit of normal (ULN)

          -  Bilirubin no greater than 1.5 mg/dL

          -  Elevated levels of alkaline phosphatase allowed

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

        Cardiovascular:

          -  No angina pectoris or clinically significant multifocal uncontrolled cardiac
             dysrhythmias

          -  No uncontrolled hypertension

        Other:

          -  No other active malignancy

          -  No prior malignancy within the past 5 years except nonmelanomatous skin cancer

          -  No active infection

          -  No underlying medical problem that would prevent compliance

          -  No known hypersensitivity to E. coli-derived drug preparations

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Must have received at least 1 prior platinum- and paclitaxel-based regimen

          -  At least 4 weeks since prior chemotherapy

          -  No prior topotecan and/or gemcitabine

          -  No prior chemotherapy for a different prior malignancy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy to more than 10% of bone marrow

          -  At least 2 weeks since limited field radiation therapy

        Surgery:

          -  Not specified
Clinical trial NCT01232439 (phase 1, status: completed)
Conditions: alcohol dependence
ICD codes: F10.20, F10.24, F10.27, F10.280, F10.281, F10.282, F10.288
Drugs: opioid receptor kappa antagonist
SMILES: CC1=CC(=CC(C)=C1)[C@@H]1CCCN1CC1=CC=C(OC2=CC=C(C=C2F)C(N)=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male or female

          -  Have clinical laboratory tests within normal reference ranges

          -  Have arterial and venous access sufficient to allow blood sampling

        Exclusion Criteria:

          -  Currently enrolled in, or discontinued within the last 30 days from a clinical trial

          -  History of severe allergies or multiple adverse drug reactions

          -  Have an abnormal ECG at screening visit

          -  Have abnormal sitting blood pressure

          -  Have an increased risk of seizures

          -  Current suicidal ideation

          -  Positive test for HIV, hepatitis C, or hepatitis B

          -  Women who are breast feeding

          -  Smoke more than 10 cigarettes per day, or equivalent

          -  Drink more than 5 cups of coffee per day, or equivalent

          -  Have a history of head injury

          -  Unable to undergo a MRI

          -  Suffer from claustrophobia
Clinical trial NCT01027234 (phase 1, status: terminated)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: azd8418, placebo
SMILES: C[C@@H](C1CC1)N1CC2=CC(=CC(Cl)=C2C1=O)C1=CC(=NO1)C(=O)N(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    pre-clinical safety tox findings
  
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male volunteers

          -  Healthy female volunteers of non-childbearing potential

        Exclusion Criteria:

          -  History of any clinically significant medical, neurologic, or psychiatric disease
             (including repeated episodes of major depression) or a disorder which, in the opinion
             of the Investigator, may either put the volunteer at risk because of participation

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as
             judged by the Investigator, or history of hypersensitivity to drugs with a similar
             chemical structure or class to AZD8418
Clinical trial NCT00633997 (phase 1/phase 2, status: terminated)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, vildagliptin
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N
Reason stopped: 
    after analysis of the existing data, it was determined that additional skin biopsy samples
    would not be required to determine study outcome.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy volunteers and patients with type 2 diabetes

          -  Non-smoking, Caucasian and African American, male and female (postmenopausal,
             surgically sterile or using double-barrier method of contraception) subjects between
             30 and 65 years of age (inclusive)

          -  Type 2 diabetics on metformin and/or sufonylurea

        Exclusion Criteria:

          -  History of type 1 diabetes or insulin use

          -  History of coagulation abnormalities

          -  History of abnormal heart conditions

          -  Pregnancy or breastfeeding

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01115712 (phase 1, status: completed)
Conditions: healthy, overweight, obesity
ICD codes: Z76.3, Z76.2, E66.3, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: placebo, comparator: pioglitazone, comparator: hyperinsulinemic euglycemic clamp
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has a BMI of greater than 28 kg/m^2 and less than or equal to 38 kg/m^2

          -  Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing
             products for at least approximately 6 months

          -  Subject is willing to avoid major dietary changes for the duration of the study

        Exclusion Criteria:

          -  Subject has history of diabetes (Type 1, Type 2 or steroid-induced)

          -  Subject has a history of hypersensitivity to pioglitazone or other thiazolidinediones

          -  Subject has a history of liver disease, other than non-alcoholic fatty liver disease
             or non-alcoholic steatohepatitis

          -  Subject has a history of congestive heart failure

          -  Subject has a active or past history of atherosclerotic heart disease, heart failure,
             osteoporosis, osteopenia, recurrent bone fractures, or anemia

          -  Subject has a history of stroke, chronic seizures, or major neurological disorder

          -  Subject has a history of clinically significant endocrine, gastrointestinal,
             cardiovascular, hematological or renal abnormalities or diseases

          -  Subject has a history of neoplastic disease within the past 5 years
Clinical trial NCT00551096 (phase 1, status: completed)
Conditions: malignant solid tumour, biliary cancer, pancreatic cancer
ICD codes: C24.9, C24.8, C25.3
Drugs: gemcitabine, capecitabine, zd6474
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 years or older

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (measure of your
             ability to perform everyday tasks)

          -  Life expectancy of at least three months

        Blood samples and other testing may apply for further testing of eligibility.

        Exclusion Criteria:

          -  Uncontrolled illness (for example, current infections or heart conditions)

          -  Abnormal laboratory tests (such as blood or urine testing)

          -  Pregnant or breastfeeding women

        Further exclusion criteria may apply.
Clinical trial NCT01199367 (phase 1, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: kw-2450 in combination with lapatinib and letrozole
SMILES: N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
Reason stopped: 
    the results of the dose escalation phase did not identify a well-tolerated dose that would
    permit further study in phase 2.
  
Eligibility criteria:

        Inclusion Criteria

          1. Histopathologically or cytologically confirmed, advanced or metastatic breast cancer
             (stage IIIb, IIIc or IV disease) including inflammatory breast cancer or inoperable
             locally advanced disease.

          2. Documented ErbB2 overexpression

          3. Estrogen receptor positive (ER+) and/or progesterone positive (PgR+) tumors

          4. Measurable or non-measurable disease according to Response Evaluation Criteria in
             Solid Tumors (RECIST) 1.1 Criteria

          5. A life expectancy of > 3 months for Phase 1 and > 6 months for Phase 2

          6. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 at study
             entry in Phase 1 and ≤ 1 in Phase 2;

          7. Normal cardiac ejection fraction

          8. Adequate hematologic, hepatic and renal function

          9. Post-menopausal female (defined as the absence of a menstrual cycle for at least 12
             consecutive months) or male subjects ≥ 18 years of age.

         10. Sign an IRB or EC approved informed consent

        Exclusion Criteria

          1. Type 1 diabetes or uncontrolled Type 2 diabetes

          2. Subjects showing clinical evidence or with a history of cataract(s), proliferate
             retinopathy or significant macular edema

          3. Subjects with abnormal free T4 values and a history or evidence of thyroid disease

          4. Subjects who are unable or unwilling to take metformin

          5. Uncontrolled intercurrent illness

          6. Known or suspected human immunodeficiency virus (HIV) infection or hepatitis B or C

          7. Subjects with inflammatory diseases of the gastrointestinal tract

          8. History of other malignancy. Subjects who have been disease free for 5 years, or
             subjects with a history of completely resected non-melanoma skin cancer or
             successfully treated in situ carcinoma are eligible;

          9. Subjects with extensive symptomatic visceral disease including hepatic involvement and
             pulmonary lymphangitic spread of tumor

         10. A history of prior treatment with other agents specifically targeting IGFRs

         11. Subjects who require pharmacological doses of glucocorticoids beyond replacement
             doses. The use of topical, intra-ocular or inhalation glucocorticoids is permitted
Clinical trial NCT01023945 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: asp1941, placebo
SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C1=CC=C(F)C(CC2=CC3=CC=CC=C3S2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetic patients for at least 12 weeks

          -  HbA1c value between 7.0 and 10.0% at screening

          -  Fasting plasma glucose ≥ 126mg/dL and < 240mg/dL at screening

          -  Body Mass Index (BMI) 20.0 - 45.0 kg/m2.

        Exclusion Criteria:

          -  Type 1 diabetes mellitus patients

          -  Serum creatinine > upper limit of normal

          -  Proteinuria（albumin/creatinine ratio > 300mg/g）

          -  Dysuria and/or urinary tract infection

          -  Significant renal, hepatic or cardiovascular diseases

          -  Severe gastrointestinal diseases
Clinical trial NCT00113529 (phase 1/phase 2, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: gefitinib + sunitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed renal cell carcinoma with metastases

          -  Evidence of unidimensionally measurable disease

          -  Failure of 1 prior immunotherapy or no prior systemic therapy for metastatic RCC

        Exclusion Criteria:

          -  RCC without any clear (conventional) cell component

          -  History of or known brain metastases

          -  Uncontrolled hypertension or other significant cardiac events within the 12 months
             prior to study entry
Clinical trial NCT01607125 (phase 1, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: vortioxetine (lu aa21004), placebo
SMILES: CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        All subjects must have:

          -  a Hamilton Depression Rating Scale (HAM-D17) total score ≤ 7

        Subjects remitted from depression must:

          -  be in remission from recurrent depression having suffered from at least two previous
             Major Depressive Episodes (MDEs)

          -  have received prescribed treatment with an antidepressant or a recognised
             psychotherapy for depression for a previous MDE

          -  report present subjective cognitive dysfunction

          -  not have been treated with antidepressants or received other psychotherapy for
             depression for at least six weeks prior to screening visit

        Control group subjects must:

          -  have no history of MDEs

          -  have no history of MDEs in a biological parent or other first degree relative as
             reported by the subject

          -  not report present subjective cognitive dysfunction

          -  never have been treated with antidepressants or psychotherapy

        Exclusion Criteria:

          -  The subject is, in the opinion of the investigator, unlikely to comply with the
             clinical study protocol or is unsuitable for any other reason

        Other inclusion and exclusion criteria may apply.
Clinical trial NCT01469923 (phase 1, status: terminated)
Conditions: obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: azd2820, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures including the genetic sampling and analyses

          -  Obese but otherwise healthy male subjects aged 18 - 45 years with suitable veins for
             cannulation or repeated venepuncture

          -  Male subjects should be willing to use barrier contraception ie, condoms, from the
             first day of dosing until 3 months after the last dose of investigational product

          -  Have a body mass index (BMI) between 27 and 40 kg/m2

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the stud

          -  A history of erectile dysfunction or anatomic abnormality of the penis (eg, cavernosal
             fibrosis, Peyronie's disease, or plaques) which interferes with normal erectile
             function

          -  Prolonged QTcF >450 ms or shortened QTcF <340 ms or family history of long QT syndrome

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as
             judged by the investigator or history of hypersensitivity to drugs with a similar
             chemical structure or class to AZD2820

          -  Any clinically significant abnormalities in clinical chemistry, haematology (including
             eosinophilia) or urinalysis results as judged by the investigator
Clinical trial NCT00003005 (phase 1, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cordycepin, deoxycoformycin
SMILES: [H][C@@]1(CO)C[C@@]([H])(O)[C@@]([H])(O1)N1C=NC2=C(N)N=CN=C12, OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O
Eligibility criteria:

        DISEASE CHARACTERISTICS: TdT positive acute lymphocytic leukemia or blastic chronic
        myelogenous leukemia Failed at least one standard treatment

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky greater than 70%
        Life expectancy: At least 3 months Hematopoietic: Not specified Hepatic: Bilirubin no
        greater than 2.0 mg/dL Transaminases no greater than 2.5 times normal Renal: Creatinine no
        greater than 1.5 mg/dL Creatinine clearance greater than 60 mL/min Cardiovascular: Ejection
        fraction greater than 40% Other: Not pregnant or nursing No serious concurrent illness

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks
        since chemotherapy No concurrent chemotherapy Endocrine therapy: Not specified
        Radiotherapy: At least 3 weeks since radiation therapy Surgery: Not specified